The Role of Genetics in Inherited Diseases and the Promise of Personalized Gene-Based Therapies

Genetics lies at the core of many inherited diseases, where mutations in single genes—such as CFTR in cystic fibrosis or HBB in sickle cell anemia—disrupt essential protein functions and cause severe clinical outcomes. Complex disorders like type 1 diabetes and Alzheimer’s disease further reveal how multiple genetic and environmental factors interact to shape disease risk. Recent breakthroughs in genomic sequencing, molecular diagnostics, and genome editing have expanded therapeutic possibilities. Personalized gene-based therapies—ranging from CRISPR-Cas9 editing for sickle cell disease to RNA-based treatments for spinal muscular atrophy—mark a shift from symptom management to precision medicine. These approaches aim to correct molecular causes directly, tailoring treatment to each patient’s genetic profile. Despite remarkable promise, obstacles remain, including high costs, unequal access, and ongoing ethical debates over germline editing and genetic privacy. Yet early clinical successes show that personalized gene therapies can move medicine beyond palliation toward prevention and cure. This paper explores how genetic understanding and personalized interventions together redefine the treatment of inherited diseases and signal a new era in precision healthcare.